Last reviewed · How we verify
Topamax® Tablets
At a glance
| Generic name | Topamax® Tablets |
|---|---|
| Sponsor | Teva Pharmaceuticals USA |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Topiramate 25 mg Tablets Under Fasting Conditions (PHASE1)
- Topiramate Bioequivalence Study Brazil - Fast (PHASE1)
- Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fasted Conditions (PHASE1)
- Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fed Conditions (PHASE1)
- A Study of the Effectiveness and Safety of Topiramate for the Prevention of Migraine (PHASE3)
- Topiramate 25 mg Tablets Under Fed Conditions (PHASE1)
- Bioequivalence Study of Topiramate Tablets 25mg Under Fasting Conditions (NA)
- Bioequivalence Study of Topiramate Tablets 25mg Under Fed Conditions (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topamax® Tablets CI brief — competitive landscape report
- Topamax® Tablets updates RSS · CI watch RSS
- Teva Pharmaceuticals USA portfolio CI